Radiation-induced fibrosis in head and neck cancer survivors: long-term sequelae and multimodal management
Abstract
IntroductionImproved survival in head and neck cancer has increased the number of patients living with late effects of treatment, among which radiation-induced fibrosis is a progressive and often irreversible complication with important consequences for pain, function, and quality of life. In addition to contributing to trismus, dysphagia, speech impairment, and reduced cervical mobility, fibrosis has important implications for airway management and perioperative care.MethodsThis narrative review synthesizes current clinical and translational literature on radiation-induced fibrosis in head and neck cancer survivorship, with emphasis on its epidemiology, underlying mechanisms, clinical manifestations, diagnosis, prevention, management, emerging therapies, and multidisciplinary care, while highlighting functional outcomes and anesthesia-relevant airway sequelae.ResultsRadiation-induced fibrosis may emerge months to years after treatment and is driven by persistent inflammatory and profibrotic signaling that promotes tissue remodeling and long-term dysfunction. Risk is influenced by patient and treatment factors including smoking, concurrent chemoradiotherapy, radiation dose and field design, surgical dissection, and baseline functional impairment. Clinically, fibrosis contributes to restricted neck motion, trismus, dysphagia, aspiration risk, dysphonia, chronic pain, and psychosocial burden. Current management is largely multimodal and supportive, centering on rehabilitation, speech and swallow therapy, symptomatic pharmacological treatment, interventional pain procedures, and selective surgery. Emerging strategies, such as antifibrotic agents, mesenchymal stromal cell therapies, hyperbaric oxygen, and candidate biomarker strategies, remain investigational but may expand future treatment options.DiscussionRadiation-induced fibrosis is an underrecognized survivorship challenge that extends beyond tissue scarring to long-term dysfunctions across airway, swallowing, pain, and quality of life domains. Future progress will depend on standardized diagnostic criteria, earlier detection, prevention-focused trials, continued evaluation of investigational therapies, and patient-centered outcomes that better capture the lived burden of survivors and guide more precise supportive care.
Related
- Early detection and management of radiation maculopathy after plaque brachytherapy for uveal melanoma: a multimodal imaging narrative review
- Outcomes of sequential microvascular tissue transfer for radiation induced sequelae post mandibular reconstruction
- The Impact of Idiopathic Pulmonary Fibrosis on the Incidence and Severity of Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Following Radiotherapy
- Early nutritional management of cystic fibrosis infants born with meconium ileus
- Integrative transcriptomic and computational analysis associates Ms4a6c+ macrophages with fibrosis in radiation proctitis and computationally nominates MOTS-c as a candidate modulator
BibTeX
@article{mohanty2026radiationinduced,
title = {{Radiation-induced fibrosis in head and neck cancer survivors: long-term sequelae and multimodal management}},
author = {Arnav Mohanty and Hunter Glover and Salahadin Abdi and Clifton D. Fuller and Billy Huh and Saba Javed},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1981918},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1981918},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Radiation-induced fibrosis in head and neck cancer survivors: long-term sequelae and multimodal management
AU - Arnav Mohanty
AU - Hunter Glover
AU - Salahadin Abdi
AU - Clifton D. Fuller
AU - Billy Huh
AU - Saba Javed
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1981918
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1981918
AB - IntroductionImproved survival in head and neck cancer has increased the number of patients living with late effects of treatment, among which radiation-induced fibrosis is a progressive and often irreversible complication with important consequences for pain, function, and quality of life. In addition to contributing to trismus, dysphagia, speech impairment, and reduced cervical mobility, fibrosis has important implications for airway management and perioperative care.MethodsThis narrative review synthesizes current clinical and translational literature on radiation-induced fibrosis in head and neck cancer survivorship, with emphasis on its epidemiology, underlying mechanisms, clinical manifestations, diagnosis, prevention, management, emerging therapies, and multidisciplinary care, while highlighting functional outcomes and anesthesia-relevant airway sequelae.ResultsRadiation-induced fibrosis may emerge months to years after treatment and is driven by persistent inflammatory and profibrotic signaling that promotes tissue remodeling and long-term dysfunction. Risk is influenced by patient and treatment factors including smoking, concurrent chemoradiotherapy, radiation dose and field design, surgical dissection, and baseline functional impairment. Clinically, fibrosis contributes to restricted neck motion, trismus, dysphagia, aspiration risk, dysphonia, chronic pain, and psychosocial burden. Current management is largely multimodal and supportive, centering on rehabilitation, speech and swallow therapy, symptomatic pharmacological treatment, interventional pain procedures, and selective surgery. Emerging strategies, such as antifibrotic agents, mesenchymal stromal cell therapies, hyperbaric oxygen, and candidate biomarker strategies, remain investigational but may expand future treatment options.DiscussionRadiation-induced fibrosis is an underrecognized survivorship challenge that extends beyond tissue scarring to long-term dysfunctions across airway, swallowing, pain, and quality of life domains. Future progress will depend on standardized diagnostic criteria, earlier detection, prevention-focused trials, continued evaluation of investigational therapies, and patient-centered outcomes that better capture the lived burden of survivors and guide more precise supportive care.
SN - 2234-943X
ER -